Cell-based treatments are life-saving therapies with the potential to offer cures for cancers and other diseases.
Metastatic spreading from solid tumors continues to be one of the greatest challenges facing oncologists and clinicians, often leading to a fatal outcome for many patients.
Immunotherapy is a diverse and broad catch-all for any treatments and therapies that utilize the patient’s own immune response to mount a defense.
Nexcelom founder and CTO, Dr. Jean Qiu, describes 3 major reasons why we partner with global and local research organizations to streamline CAR-T workflow.
Poster: High-throughput immune complex analysis method for CAR T cell-mediated cytotoxicity using the Celigo Image Cytometer
Download our Poster Abstract: Cancer immunotherapy has been gaining momentum in the field of cancer research. Specifically, Chimeric Antigen Receptor (CAR) T cell technology have introduced new methods to combat cancer. Direct cell-mediated cytotoxicity assays are required to assess the killing capability of the engineered CAR T cells. Traditionally, these assays are conducted by measuring the amount of released Chromium, calcein AM, or LDH molecules after the target cancer cells are killed with CAR T cells. These methods require a large amount of target cells which may not be ideal when working with donor primary samples. Additionally, they cannot [...]